Skip to main content
. 2021 May 27;11:618570. doi: 10.3389/fonc.2021.618570

Table 2.

Immune-related adverse events within 6 weeks of initiating nivolumab treatment.

Event Patients (N = 171)
Any irAE, N (%) 73 (42.7)
 Skin reaction 44 (25.7)
 Diarrhea 20 (11.7)
 Thyroiditis/hypothyroidism 15 (8.8)
 Liver dysfunction 3 (1.8)
 Pneumonitis 2 (1.2)
 Encephalitis 1 (0.6)
 Myasthenia gravis 1 (0.6)
 Venous blood thromboembolism 1 (0.6)

irAE, immune-related adverse event.